Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Thyroid Cancer Clinical Trial

Official title:

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02156362
• Other study ID #: 2011.665
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 2012
• Est. completion date: May 2023

Study information

• Verified date: January 2021
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.

The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 643
• Est. completion date: May 2023
• Est. primary completion date: May 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Man or woman = 18 years.

• Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).

• TNM classification: stage pT3 (=2 cm), or pT4 or M1 at diagnosis.

• Patient after post operative radioiodine therapy.

Exclusion Criteria:

• Patient who can not be followed during the protocol.

• Patient who does not consent.

Related Conditions & MeSH terms

• Carcinoma
• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Other:
• follow up visit
At least 1 follow up visit per year will be done and an additional visit if needed.

Locations

Country	Name	City	State
France	Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel	Bron cedex

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Thyroid cancer evolving to refractory stage		5 years